(Adds details from conference call, background; updates share price)
By Tamara Mathias and Caroline Humer
May 28 (Reuters) – BioMarin Pharmaceutical Inc said on Tuesday data from an early study of its gene therapy for hemophilia A appeared to show blood clotting protein levels were stable, three years after patients were given a one-time infusion of the drug.
The company is expected to price the drug, valoctocogene roxaparvovec, at over $1 million for a single dose, but investors are focused on whether the effects of the treatment will last long enough to command such a high price.
The data suggest the value of the drug is equivalent to five-year cost of standard treatment for hemophilia, which the company said averaged about $400,000 for adults, Chief